Hypoxia, clonal selection, and the role of HIF-1 in tumor progression

Critical Reviews in Biochemistry and Molecular Biology

Volumn 35, Issue 2, 2000, Pages 71-103

  Semenza, Gregg L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Angiogenesis; Cancer; Glycolysis p53; Ras; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANGIOGENESIS; GENE ACTIVATION; GLYCOLYSIS; HYPOXIA; METASTASIS; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0034021690     PISSN: 10409238     EISSN: None     Source Type: Journal    
DOI: 10.1080/10409230091169186     Document Type: Review

References (209)

1. Abdulrauf, S. I., Edvardsen, K., Ho, K. L., Yang, X. Y., Rock, J. P., and Rosenblum, M. L. 1998. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J. Neurosurg. 88:513-520.
2. Agani, F., Kirsch, D. G., Friedman, S. L., Kastan, M. B., and Semenza, G. L. 1997. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res. 57:4474-4477.
3. Agani, F. and Semenza, G. L. 1998. Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol. Pharmacol. 54:749-754.
4. An, W., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. 1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392:405-408.
5. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. 1997. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72:1-22.
6. Arany, Z., Huang, L. E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M. A., Bunn, H. F., and Livingston, D. M. 1996. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. U.S.A. 93:12969-12973.
7. Arap, W., Pasqualini, R., and Ruoslahti, E. 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380.
8. Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H. R., and Folkman, J. 1997. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 94:861-866.
9. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. 1999. Selective ablation of immature blood vessels in established tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-165.
10. Benjamin, L. E. and Keshet, E. 1997. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. U.S.A. 94:8761-8766.
11. Bergers, G., Javaherian, K., Lo, K-M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812.
12. Bhattacharya, S., Michels, C. L., Leung, M-K., Arany, Z. P., Kung, A. L., and Livingston, D. M. 1999. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 13:64-75.
13. Blagosklonny, M. V. 1999. A node between proliferation, apoptosis, and growth arrest. BioEssays 21:704-709.
14. Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T., and Neckers, L. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273:1199511998.
15. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407.
16. Borgstrom, P., Hillan, K. J., Sriramarao, P., and Ferrara, N. 1996. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56:4032-4039.
17. Bouck, N. 1996. P53 and angiogenesis. Biochim. Biophys. Acta 1287:63-66.
18. Bouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., Fang, B., Lee, J. J., and Roth, J. A. 1998. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58:2288-2292.
19. Brand, K. A. and Hermfisse, U. 1997. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 11:388-395.
20. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and Dewhirst, M. W. 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:941-943.
21. Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., and Darnell, J. E., Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18:2553-2558.
22. Brown, E. J. and Schreiber, S. L. 1996. A signaling pathway to translational control. Cell 86:517-520.
23. Brown, J. M. and Giaccia, A. J. 1994. Tumor hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol. 65:95-102.
24. Brown, J. M., and Giaccia, A. J. 1998. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:1408-1416.
25. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:263-269.
26. Buolamwini, J. K. 1999. Novel anticancer drug discovery. Curr. Opin. Chem. Biol. 3:500-509.
27. Cantley, L. C. and Neel, B. G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U.S.A. 96:4240-4245.
28. Cardenas, M. E., Sanfridson, A., Cutler, N. S., and Heitman, J. 1998. Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 16:427-433.
29. Carmeliet, P., Dor, Y., Herbert, J-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., and Keshet, E. 1998. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis. Nature 394:485-490.
30. Carrero, P., Okamoto, K., Coumailleau, P., O'Brien, S., Tanaka, H., and Poellinger, L. 2000. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor la. Mol. Cell. Biol. 20:402-415.
31. Carroll, R. C., Ash, J. F., Vogt, P. K., and Singer, S. J. 1978. Reversion of transformed glycolysis to normal by inhibition of protein synthesis in rat kidney cells infected with temperature-sensitive mutant of Rous sarcoma virus. Proc. Natl. Acad. Sci. U.S.A. 75:5015-5019.
32. Cheng, S-Y., Huang, H-J. S., Nagane, M., Ji, X-D., Wang, D., Shih, C. C-Y., Arap, W., Huang, C-M., and Cavenee, W. K. 1996. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U.S.A. 93:8502-8507.
33. Conrad, P. W., Freeman, T. L., Beitner-Johnson, D., and Millhorn, D. E. 1999. EPAS1 transactivation during hypoxia requires p42/p44 MAPK. J. Biol. Chem. 274:33709-33713.
34. Cormier-Regard, S., Nguyen, S. V., and Claycomb, W. C. 1998. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J. Biol. Chem. 273:17787-17792.
35. Crews, S. T. and Fan, C-M. 1999. Remembrance of things PAS: regulation of development by bHLH-PAS proteins. Curr. Opin. Genet. Dev. 9:580-587.
36. Crowley, C. W., Cohen, R. L., Lucas, B. K., Liu, G., Shuman, M. A., and Levinson, A. D. 1993. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. U.S.A. 90:5021-5025.
37. Czernilofsky, A. P., Levinson, A. D., Varmus, H. E., Bishop, J. M., Tischer, E., and Goodman, H. M. 1980. Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature 287:198-203.
38. Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M. S., Stratford, I. M., and Harris, A. L. 1997. Targeting gene expression to hypoxic tumor cells. Nat. Med. 3:515-520.
39. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584.
40. Dang, C. V. and Semenza, G. L. 1999. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24:68-72.
41. Ebert, B. L., Firth, J. D., and Ratcliffe, P. J. 1995. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J. Biol. Chem. 270:29083-29089.
42. 1B-adr-energic receptor gene promoter region and hypoxia regulatory elements in vascular smooth muscle. Proc. Natl. Acad. Sci. U.S.A. 94:9487-9492.
43. Ellis, L. M., Staley, C. A., Liu, W., Fleming, R. Y., Parikh, N. U., Bucana, C. D., and Gallick, G. E. 1998. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem. 273:1052-1057.
44. Ema, M., Hirota, K., Mimura, J., Abe, H., Yodoi, J., Sogawa, K., Poellinger, L., and Fujii-Kuriyama, Y. 1999. Molecular mechanisms of transcription activation by HLF and HIF-1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18:1905-1914.
45. Evans, C. P., Elfman, F., Parangi, S., Conn, M., Cunha, G., and Shuman, M. A. 1997. Inhibition of prosate cancere neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res. 57:3594-3599.
46. Feldkamp, M. M., Lau, N., Rak, J., Kerbel, R. S., and Guha, A. 1999. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer 81:118-124.
47. Feldser, D., Agani, F., Iyer, N. V., Pak, B., Ferreira, G., and. Semenza, G. L. 1999. Reciprocal postive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res. 59:3915-3918.
48. Ferrara, N. and Davis-Smyth, T. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18:4-25.
49. Fidler, I. J. and Ellis, L. M. 1994. The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188.
50. Finco, T. S., Westwick, J. K., Morris, J. L., Beg, A. A., Der, C. J., and Baldwin, A. S., Jr. 1997. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272:24113-24116.
51. Firth, J. D., Ebert, B. L., Pugh, C. W., and Ratcliffe, P. J. 1994. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc. Natl. Acad. Sci. U.S.A. 91:6496-6500.
52. Firth, J. D., Ebert, B. L., and Ratcliffe, P. J. 1995. Hypoxic regulation of lactate dehydrogenase A. J. Biol. Chem. 270:21021-21027.
53. Flamme, I., Krieg, M., and Plate, K. H. 1998. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α. Am. J. Pathol. 153:25-29.
54. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182-1186.
55. Folkman, J. 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
56. Folkman, J. 1992. The role of angiogenesis in tumor growth. Sem. Cancer Biol. 3:65-71.
57. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
58. Forsythe, J. A., Jiang, B-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604-4613.
59. Fox, S. B. 1997. Tumor angiogenesis and prognosis. Histopathology 30:294-301.
60. Gerber, H-P., Condorelli, F., Park, J., and Ferrara, N. 1997. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes: Flt-1, but not Flk-1/KDR, is upregulated by hypoxia. J. Biol. Chem. 272:23659-23667.
61. Giaccia, A. J. and Kastan, M. B. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:2973-2983.
62. Gillies, R. J., Schornack, P. A., Secomb, T. W., and Raghunand, N. 1999. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1:197-207.
63. Giri, D. and Ittmann, M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum. Pathol. 30:419-424, 1999.
64. Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F. M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J.,D., Isaacs, W. B., Lerman, M. I., Zbar, B., and Linehan, W. M. 1994. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat. Genet. 7:85-90.
65. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., and Linehan, W.M. 1996. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. U.S.A. 93:10589-10594.
66. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91.
67. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14:6264-6277.
68. Graham, C. H., Fitzpatrick, T. E., and McCrae, K. R. 1998. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 91:3300-3307.
69. Graham, C. H., Forsdike, J., Fitzgerald, C. J., and Macdonald-Goodfellow, S. 1999. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer 80:617-623.
70. Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. 1998. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2:405-415.
71. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marme, D. 1995. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270:25915-25919.
72. Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D., and Johnson, R. S. 1999. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59:1592-1598.
73. Hanahan, D. and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
74. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
75. Hellwig-Burgel, T., Rutkowski, K., Metzen, E., Fandrey, J., and Jelkmann, W. 1999. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor 1. Blood 94:1561-1567.
76. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a alack of correlation. Nature Med. 3:177-182.
77. Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., Linehan, W. M., and Baylin, S. B. 1994. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. U.S.A. 91:9700-9704.
78. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509-4515.
79. Hoffman, E. C., Reyes, H., Chu, F.-F., Snader, F,, Conley, L. H., Brooks, B. A., and Hankinson, O. 1991. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252:954-958.
80. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. 1991. p53 mutations in human cancers. Science 253:49-53.
81. Hu, J., Discher, D. J., Bishopric, N. H., and Webster, K. A. 1998. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem. Biophys. Res. Commun. 245:894-899.
82. Huang, L. E., Arany, Z., Livingston, D. M., and Bunn, H. F. 1996. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J. Biol. Chem. 271:32253-32259.
83. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 95:7987-7992.
84. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr., and Goldberg, M. A. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U.S.A. 93:19595-10599.
85. Im, S. A., Gomez-Manzano, C., Fueyo, J., Liu, T. J., Ke, L. D., Kim, J. S., Lee, H. Y., Steck, P. A., Kyritsis, A. P., and Yung, W. K. 1999. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 59:895-900.
86. Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., and Yeatman, T. J. 1999. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21:187-190.
87. Iwai, K., Yamanaka, K., Kamura, T., Minato, N., Conaway, R. C., Conaway, J. W., Klausner, R. D., and Pause, A. 1999. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. U.S.A. 96:12436-12441.
88. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12:149-162.
89. Jackson, J. R., Minton, J. A. L., Ho, M. L., Wei, N., and Winkler, J. D. 1997. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1β. J. Rheumatol. 24:1253-1259.
90. Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., and Keshet, E. 1998. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U.S.A. 95:10820-10825.
91. Jekunen, A. P. and Kairemo, K. J. A. 1997. Inhibition of malignant angiogenesis. Cancer Treat. Rev. 23:263-286.
92. Jiang, B-H., Agani, F., Passaniti, A., and Semenza, G. L. 1997a. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328-5335.
93. Jiang, B-H., Rue, E., Wang, G. L., Roe, R., and Semenza, G. L. 1996a. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271:17771-17778.
94. 2 tension. Am. J. Physiol. 271:C1172-C1180.
95. Jiang, B-H., Zheng, J. Z., Leung, S. W., Roe, R., and Semenza, G. L. 1997b. Transactivation and inhibitory domains of hypoxia-inducible factor 1α: modulation of transcriptional activity by oxygen tension. J. Biol.Chem. 272:19253-19260.
96. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., and Poellinger, L. 1999. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:6519-6525.
97. Kanno, H., Kondo, K., Ito, S., Yamamoto, I., Fujii, S., Torigoe, S., Sakai, N., Hosaka, M., Shuin, T., and Yao, M. 1994. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res. 54:4845-4847.
98. Keshet, E. and Ben-Sasson, S. A. 1999. Anticancer drug targets: approaching angiogenesis. J. Clin. Invest. 104:1497-1501.
99. Kietzmann, T., Roth, U., and Jungermann, K. 1999. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94:4177-4185.
100. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844.
101. Kim, K. W., Bae, S. K., Lee, O. H., Bae, M. H., Lee, M. J., and Park, B. C. 1998. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 58:348-351.
102. Kozak, K. R., Abbott, B., and Hankinson, O. 1997. ARNT-deficient mice and placental differentiation. Dev. Biol. 191:297-305.
103. Krieg, M., Marti, H. H., and Plate, K. H. 1998. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92:3388-3393.
104. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
105. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F., Li, H., Wei, M. H., Chen, F., Glenn, G., Choyke, P., Walther, M. M., Weng, Y., Duan, D. R., Dean, M., Glavac, D., Richards, F. M., Crossey, P. A., Ferguson-Smith, M. A., Le Paslier, D., Chumakov, I., Cohen, D., Chinault, A. C., Maher, E. R., Linehan, W. M., Zbar, B., and Lerman, M. I. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
106. Lee, P. J., Jiang, B-H., Chin, B. Y., Iyer, N. V., Alam, J., Semenza, G. L., and Choi, A. M. K. 1997. Hypoxia-inducible factor 1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J. Biol. Chem. 272:5375-5381.
107. Leung, S. Y., Chan, A. S., Wong, M. P., Yuen, S. T., Cheung, N., and Chung, L. P. 1997. Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma. Am. J. Surg. Pathol. 21:941-950.
108. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
109. Levine, A. J., Momand, J., and Finlay, C. A. 1991. The p53 tumor suppressor gene. Nature 351:453-456.
110. Levy, A. P., Levy, N. S., Wegner, S., and Goldberg, M. A. 1995. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270: 13333-13340.
111. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated inhuman brain, breast, and prostate cancer. Science 275: 1943-1947.
112. Liang, B. C. 1996. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J. Neurooncol. 29:149-155.
113. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M., and Krek, W. 1999. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13:1822-1833.
114. Liu, Y., Cox, S.R., Morita, T., and Kourembanas, S. 1995. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Circ. Res. 77: 638-643.
115. Lok, C. N. and Ponka, P. 1999. Identification of a hypoxia response element in the transferrin receptor gene. J. Biol. Chem. 274:24147-24152.
116. Maltepe, E., Schmidt, J. V., Baunoch, D., Bradfield, C. A., and Simon, M. C. 1997. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403-407.
117. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. 1997. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 94:8104-8109.
118. Maxwell, P. H., Wiesener, M. S., Chang, G-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. 1999. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
119. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90:3322-3331.
120. Mazure, N. M., Chen, E. Y., Yen, P., Laderoute, K. R., and Giaccia, A. J. 1996. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56:3436-3440.
121. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers, W. R. 1999. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59:4291-4296.
122. Melillo, G., Musso, T., Sica, A., Taylor, L. S., Cox, G. W., and Varesio, L. 1995. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182:1683-1693.
123. Milanini, J., Vinals, F., Pouyssegur, J., and Pages, G. 1998. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273:18165-18172.
124. Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., and Strawn, L. M. 1996. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1615-1620.
125. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579.
126. Min, H. Y., Doyle, L. V., Vitt, C. R., Zondonella, C. L., Stratton-Thomas, J. R., Shuman, M. A., and Rosenberg, S. 1996. Urokinase receptor antagonists inhibit angiogenesis and primary growth in syngeneic mice. Cancer Res. 56:2428-2433.
127. Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V. P. 1995. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55:6161-6165.
128. Nowell, P. C. 1976. The clonal evolution of tumor cell populations. Science 194:23-28.
129. Ohh, M. and Kaelin, W. G., Jr. 1999. The von Hippel-Lindau tumor suppressor protein: new perspectives. Mol. Med. Today 5:257-263.
130. Okada, F., Rak, J. W., St. Croix, B., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. 1998. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 95:3609-3614.
131. Oliff, A. 1999. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta 1423:C19-C30.
132. Ossowski, L., Clunie, G., Masucci, M. T., and Blasi, F. 1991. In vivo paracrine interactions between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 115:1107-1112.
133. Palmer, L. A., Semenza, G. L., Stoler, M. H., and Johns, R. A. 1998. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am. J. Physiol. 274:L212-L219.
134. Penuel, E. and Martin, G. S. 1999. Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. Mol. Biol. Cell 10:1693-1703.
135. Pietsch, T., Valter, M. M., Wolf, H. K., von Deimling, A., Huang, H. J., Cavenee, W. K., and Wiestler, O. D. 1997. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol. (Berlin) 93:109-117.
136. Plate, K. H. Breier, G., Weich, H. A., and Risau, W. 1992. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359:845-848.
137. Plate, K. H. and Mennel, H. D. 1995. Vascular morphology and angiogenesis in glial tumors. Exp. Toxicol. Pathol. 47:89-94.
138. Plate, K. H., and Warnke, P. C. 1997. Vascular endothelial growth factor. J. Neurooncol. 35:365-372.
139. Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M., and Ratcliffe, P. J. 1997. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J. Biol. Chem. 272:11205-11214.
140. Racker, E., Resnick, R. J., and Feldman, R. 1985. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc. Natl. Acad. Sci. U.S.A. 82:3535-3538.
141. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. 1995. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55:4575-4580.
142. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia - inducible factor 1α. Genes Dev. 14:34-44.
143. Richard, D. E., Berra, E., Gothie, E., Roux, D., and Pouyssegur, J. 1999. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274:32631-32637.
144. Rolfs, A., Kvietikova, I., Gassmann, M., and Wenger, R. H. 1997. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J. Biol. Chem. 272:20055-20062.
145. Ryan, H. E., Lo, J., and Johnson, R. S. 1998. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17:3005-3015.
146. Ryuto, M., Ono, M., Izumi, H., Yoshida, S., Weich, H. A., Kohno, K., and Kuwano, M. 1996. Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells. J. Biol. Chem. 271:28220-28228.
147. Salceda, S. Beck, I., and Caro, J. 1996. Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. Arch. Biochem. Biophys. 334: 389-394.
148. Salceda, S., and Caro, J. 1997. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: its stabilization by hypoxia depends upon redox-induced changes. J. Biol. Chem. 272: 22642-22647.
149. Saleh, M., Stacker, S. A., and Wilks, A. F. 1996. Inhibition of growth of C6 glioma cells in viov by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56:393-401.
150. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
151. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
152. Schmaltz, C., Hardenbergh, P. H., Wells, A., and Fisher, D. E. 1998. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol. 18:2845-2854.
153. Schwickert, G., Walenta, S., Sundfor, K., Rofstad, E. K., and Mueller-Klieser, W. 1995. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 55:4757-4759.
154. Semenza, G. L. 1998. Transcription Factors and Human Disease. Oxford University Press, New York.
155. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Devel. Biol. 15:551-578.
156. Semenza, G. L. 2000. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 59:47-53.
157. Semenza, G. L., Jiang, B-H., Leung, S. W., Passantino, R., Concordet, J-P., Maire, P., and Giallongo, A. 1996. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271:32529-32537.
158. Semenza, G. L., Roth, P. H., Fang, H-M., and Wang, G. L. 1994. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269:23757-23763.
159. Semenza, G. L. and Wang, G. L. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12:5447-5454.
160. Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G., and Ellis, L. M. 1999. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor inhibits the growth of colon cancer liver metastases and induces tumor and endothelial cell apoptosis. Cancer Res. 59:5412-5416.
161. Shim, H., Dolde, C., Lewis, B. C., Wu, C-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., and Dang, C. V. 1997. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. U.S.A. 94:6658-6663.
162. Shima, D. T., Kuroki, M., Deutsch, U., Ng, Y-S., Adamis, A. P., and D'Amore, P. A. 1996. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 271:3877-3883.
163. Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M., Nagashima, Y., Kitamura, H., Latif, F., Zbar, B., et al. 1994. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary renal cell carcinomas. Cancer Res. 54:2852-2855.
164. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
165. Singh, V. N., Singh, M., August, J. T., and Horecker, B. L. 1974. Alterations in glucose metabolism in chick-embryo cells transformed by Rous sarcoma virus: intracellular levels of glycolytic intermediates. Proc. Natl. Acad. Sci. U.S.A. 71:4129-4132.
166. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N. E. 1997. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3:1222-1227.
167. Stavri, G. T., Hong, Y., Zachary, I. C., Breier, G., Baskerville, P. A., Yla-Herttuala, Risau, W., Martin, J. F., and Erusalimsky, J. D. 1995a. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 358:311-315.
168. Stavri, G. T., Zachary, I. C., Baskerville, P. A., Martin, J. F., and Erusalimsky, J. D. 1995b. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation 92:11-14.
169. Steck, T. L., Kaufman, S., and Bader, J. P. 1968. Glycolysis in chick embryo cell cultures transformed by Rous sarcoma virus. Cancer Res. 28:1611-1619.
170. Stehelin, D., Varmus, H. E., Bishop, J. M., and Vogt, P. K. 1976. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260:170-173.
171. Stratmann, R., Krieg, M., Haas, R., and Plate, K. H. 1997. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J. Neuropathol. Exp. Neurol. 56:1242-1252.
172. Sutter, C.H., Laughner, E., and Semenza, G.L 2000. Hypexia-inducible factor 1α protein expression is controlled by oxyegen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. U.S.A., in press.
173. Swanstrom, R., Parker, R. C., Varmus, H. E., and Bishop, J. M. 1983. Transduction of a cellular oncogene: the genesis of Rous sarcoma virus. Proc. Natl. Acad. Sci. U.S.A. 80:2519-2523.
174. Tacchini, L., Bianchi, L., Bernelli-Zazzera, A., and Cairo, G. 1999. Transferrin receptor induction by hypoxia: HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J. Biol. Chem. 274:24142-24146.
175. Takahashi, Y., Bucana, C. D., Cleary, K. R., and Ellis, L. M. 1998. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int. J. Cancer 79:34-38.
176. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S., and Nose, T. 1996. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56:2185-2190.
177. Takekawa, Y. and Sawada, T. 1998. Vascular endothelial growth factor and neovascularization in astrocytic tumors. Pathol. Int. 48:109-114.
178. Tazuke, S. I., Mazure, N. M., Sugawara, J., Garland, G., Faessen, G. H., Suen, L.-F., Irwin, J. C., Powell, D. R., Giaccia, A. J., and Giudice, L. C. 1998. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxa. Proc. Natl. Acad. Sci. U.S.A. 95:10188-10193.
179. Theurillat, J-P., Hainfellner, J., Maddalena, A., Weissenberger, J., and Aguzzi, A. 1999. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am. J. Pathol. 154:581-590.
180. Thrash-Bingham, C. A. and Tartof, K. D. 1999. aHIF: a natural antisense transcript overexpressed in human renal cell cancer and during hypoxia. J. Natl. Cancer Inst. 91:143-151.
181. Tian, H., Hammer, R. E., Matsumoto, A. M., Russell, D. W., and McKnight, S. L. 1998. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12:3320-3324.
182. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., and Jove, R. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18:2545-2552.
183. Van Meir, E. G., Polverini, P. J., Chazin, V. R., Huang, H-J. S., de Tribolet, N., and Cavenee, W. K. 1994. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat. Genet. 8:171-176.
184. Vaupel, P. 1996. Oxygen transport in tumors. Adv. Exp. Med. Biol. 388:341-356.
185. Vaupel, P., Kallinowski, F., and Okunieff, P. 1989. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49:6449-6465.
186. Venuta, S. and Rubin, H. 1973. Sugar transport in normal and Rous sarcoma virus-transformed chick-embryo fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 70:653-657.
187. Vogelstein, B. and Kinzler, K. W., Eds. 1998. The Genetic Basis of Human Cancer. McGraw-Hill, New York.
188. Walenta, S., Salameh, A., Lyng, H., Evensen, J. F., Mitze, M., Rofstad, E. K., and Mueller-Klieser, W. 1997. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am. J. Pathol. 150:409-415.
189. 2 tension. Proc. Natl. Acad. Sci. U.S.A. 92:5510-5514.
190. Wang, G. L., Jiang, B-H., and Semenza, G. L. 1995b. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 216:669-675.
191. Wang, G. L. and Semenza, G. L. 1993. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA binding activity: implications for models of hypoxia signal transduction. Blood 82:3610-3615.
192. Wang, G. L., and Semenza, G. L. 1995. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270:1230-1237.
193. Warburg, O. 1930. The Metabolism of Tumours (translated from the German edition by F. Dickens). Constable and Co., Ltd., London.
194. Warren, R. S., Yuan, H., Matli, M. R., Ferrara, N., and Donner, D. B. 1996. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. 271:29483-29488.
195. Weber, M. J. 1973. Hexose transport in normal and in Rous sarcoma virus-transformed cells. J. Biol. Chem. 248:2978-2983.
196. Wizigmann-Voos, S., Breier, G., Risau, W., and Plate, K. H. 1995. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55:1358-1364.
197. Wood, S. M., Gleadle, J. M., Pugh, C. W., Hankinson, O., and Ratcliffe, P. J. 1996. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression: studies in ARNT-deficient cells. J. Biol. Chem. 271:15117-15123.
198. Wood, S. M., Wiesener, M. S., Yeates, K. M., Okada, N., Pugh, C. W., Maxwell, P. H., and Ratcliffe, P. J. 1998. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1α-subunit (HIF-1α): characterization of HIF-1α-dependent and independent hypoxia-inducible gene expression. J. Biol. Chem. 273:8360-8368.
199. Xing, J., Ginty, D. D., and Greenberg, M. E. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273:959-963.
200. Yu, A. Y., Frid, M. G., Shimoda, L. A., Wiener, C. M., Stenmark, K., and Semenza, G. L. 1998. Temporal, spatial and oxygen-regulated expression of hypoxia-inducible factor 1 in the lung. Am. J. Physiol. 275:L818-L826.
201. Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., and Jain, R. K. 1996. Time-dependent vascular regression and permeability changes in established tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. U.S.A. 93:14765-14770.
202. Yuan, J. and Glazer, P. M. 1998. Mutagenesis induced by the tumor microenvironment. Mutation Res. 400:439-446.
203. Zagzag. D., Zhong, H., Scalzitti, J.M., Laughner, E. Sinons, J.W., and Semenza, G.L. 2000. Espression of hypoxia-inducible factor 1α in human brain tumors: association with angiogenesis, invasion, and progression. Cancer, in press.
204. Zelzer, E., Levy, Y., Kahana, C., Shilo, B-Z., Rubinstein, M, and Cohen, B. 1998. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J. 17:5085-5094.
205. Zetter, B. R. 1998. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49:407-424.
206. Zhang, L., Zhou, W., Velculescu, V. E., Kern, S. E., Hruban, R. H., Hamilton, S. R., Vogelstein, B., and Kanzler, K. W. 1997. Gene expression profiles in normal and cancer cells. Science 276:1268-1272.
207. Zhong, H., Agani, F., Baccala, A. A, Laughner, E., Rioseco-Camacho, N., Isaacs, W. B., Simons, J. W., and Semenza, G. L. 1998. Increased expression of hypoxia-inducible factor 1α in rat and human prostate cancer. Cancer Res. 58:5280-5284.
208. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M.-M., Simons, J. W., and Semenza, G. L. 2000. Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60: 1541-1545.
209. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. 1999. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59:5830-5835.